Barclays PLC increased its position in shares of Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA – Free Report) by 294.2% during ...

EDP-235 is under clinical development by Enanta Pharmaceuticals and currently in Phase II for Coronavirus Disease 2019 (COVID-19).

Enanta Pharmaceuticals (ENTA) announced Tuesday it would appeal a recent U.S. federal court ruling that favored Pfizer ...

Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA – Get Free Report) has earned a consensus rating of “Moderate Buy” from the five ...

Enanta Pharmaceuticals, Inc. (NASDAQ: ENTA), a clinical-stage biotechnology company dedicated to creating small molecule ...

Enanta Pharmaceuticals Inc (ENTA) stock saw a decline, ending the day at $5.75 which represents a decrease of $-0.10 or -1.71% from the prior close of $5.85. The stock opened at $6 and touched a low ...

Enanta Pharmaceuticals (ENTA) shares rallied 7.2% in the last trading session to close at $6.28. This move can be attributable to notable volume with a higher number of shares being traded than in a ...

H.C. Wainwright lowered the firm’s price target on Enanta (ENTA) to $18 from $27 and keeps a Buy rating on the shares. Zelicapavir successfully ...

WATERTOWN, Mass.--(BUSINESS WIRE)--Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA), a clinical-stage biotechnology company dedicated to creating small molecule drugs for virology and immunology ...

Enanta Pharmaceuticals plans to appeal a court decision that Pfizer's Covid-19 antiviral drug, Paxlovid, doesn't infringe on its own patents. The U.S. District Court of Massachusetts ruled that Pfizer ...

The live webcast on Monday, December 9 at 8:30 a.m. ET can be accessed at "Events & Presentations" in the investors section of Enanta’s website. To participate by phone, please register for the ...

Enanta Pharmaceuticals (ENTA) announced that the United States District Court of Massachusetts has issued a ruling on a summary judgment motion ...